Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709239 · ClinicalTrials.gov registry record · NA
Prenatal DHA and Neurofunctional Development
A NA study of Use and Dose of Prenatal DHA Supplementation, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 1
- Study location
NCT02709239: Completed NA study of Use and Dose of Prenatal DHA Supplementation, sponsored by University of Kansas Medical Center.
NCT02709239 is a NA study of Use and Dose of Prenatal DHA Supplementation that has completed, run by University of Kansas Medical Center. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02709239, a NA study of Use and Dose of Prenatal DHA Supplementation, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn how much DHA to give to mothers in order to provide enough to the baby. Researchers will also learn if there are differences in development of the baby up to 12 months after birth.
Primary Outcome
Maternal blood samples and infant cord blood will be collected at delivery and Red Blood Cell (RBC) DHA concentrations between maternal-infant pairs will be compared. Maternal-Infant DHA Equilibrium occurs if newborn cord blood DHA is less than or equal to the mother's DHA at delivery.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT DHA 200mg
- DIETARY_SUPPLEMENT DHA 800mg
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2021-08-16 |
| Phase | NA |
What the finished NCT02709239 record still lists
NCT02709239 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Use and Dose of Prenatal DHA Supplementation appearing as the primary indexed condition, and to 2 interventions - of which DHA 200mg is the first listed.
NCT02709239 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT02709239 about?
NCT02709239 is a clinical study titled "Prenatal DHA and Neurofunctional Development". The purpose of this study is to learn how much DHA to give to mothers in order to provide enough to the baby. Researchers will also learn if there are differences in development of the baby up to 12 months after birth.
What is the current status of trial NCT02709239?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2016-06-01. Estimated completion is 2021-08-16.
What conditions does trial NCT02709239 study?
This clinical trial studies the following conditions: Use and Dose of Prenatal DHA Supplementation.
What interventions are being tested in trial NCT02709239?
The interventions under investigation include: DHA 200mg (DIETARY_SUPPLEMENT), DHA 800mg (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02709239?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02709239 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02709239's enrollment target sits among peer trials
300 330th of 2000 higher than 1,630 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI